{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:41:58Z","timestamp":1791387718533,"version":"4.3.3"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81272901"],"award-info":[{"award-number":["81272901"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Open Project of State Key Laboratory of Respiratory Disease","award":["SKLRD2016OP011"],"award-info":[{"award-number":["SKLRD2016OP011"]}]},{"DOI":"10.13039\/501100012245","name":"Science and Technology Planning Project of Guangdong Province","doi-asserted-by":"crossref","award":["2014A020212340"],"award-info":[{"award-number":["2014A020212340"]}],"id":[{"id":"10.13039\/501100012245","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.lungcan.2016.10.015","type":"journal-article","created":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T05:45:24Z","timestamp":1477979124000},"page":"101-107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["Coexistence of p16\/CDKN2A homozygous deletions and activating EGFR mutations in lung adenocarcinoma patients signifies a poor response to EGFR-TKIs"],"prefix":"10.1016","volume":"102","author":[{"given":"Juhong","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruibin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubao","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"August (8)","key":"10.1016\/j.lungcan.2016.10.015_bib0005","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1158\/1055-9965.EPI-10-0437","article-title":"Global patterns of cancer incidence and mortality rates and trends","volume":"19","author":"Jemal","year":"2010","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"March (2)","key":"10.1016\/j.lungcan.2016.10.015_bib0010","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3322\/caac.21338","article-title":"Cancer statistics in China, 2015","volume":"66","author":"Chen","year":"2016","journal-title":"CA. Cancer J. Clin."},{"issue":"January (1)","key":"10.1016\/j.lungcan.2016.10.015_bib0015","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA. Cancer J. Clin."},{"issue":"16","key":"10.1016\/j.lungcan.2016.10.015_bib0020","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1200\/JCO.2003.12.046","article-title":"Randomized, multinational, phase III study of docetaxel plus patinnum combinations versus vinorelbine plus cisplatin for advanced NSCLC: the TAX326 Study Group","volume":"21","author":"Fossella","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2016.10.015_bib0025","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.3816\/CLC.2005.s.014","article-title":"First-line chemotherapy for advanced-stage non-small cell lung cancer: focus on docetaxel","volume":"7","author":"Ramalingarm","year":"2005","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2016.10.015_bib0030","doi-asserted-by":"crossref","first-page":"457418","DOI":"10.1155\/2009\/457418","article-title":"Non-cross resistant sequential single agent chemotherapy in first-line advanced non-Small cell lung cancer patients: results of a phase II study","volume":"2009","author":"Surmont","year":"2009","journal-title":"J. Oncol."},{"key":"10.1016\/j.lungcan.2016.10.015_bib0035","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/sj.bjc.6603393","article-title":"A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations","volume":"95","author":"Asahina","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lungcan.2016.10.015_bib0040","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1517\/13543784.17.3.401","article-title":"Chang AY: The role of gefitinib in the management of Asian patients with non-small cell lung cancer","volume":"17","year":"2008","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.lungcan.2016.10.015_bib0045","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1200\/JCO.2005.05.4692","article-title":"Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations","volume":"24","author":"Inoue","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2016.10.015_bib0050","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1200\/JCO.2006.07.5754","article-title":"Phase II clinical trial of chemotherapy-naive patients or 70 years of age treated with erlotinib for advanced non-small-cell lung cancer","volume":"25","author":"Jackman","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2016.10.015_bib0055","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.lungcan.2007.01.025","article-title":"Phase II prospective study of the efficacy of gefitinib for the treatment of stage III\/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy","volume":"56","author":"Sunaga","year":"2007","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2016.10.015_bib0060","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S1556-0864(15)30013-7","article-title":"Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer","volume":"2","author":"Yoshida","year":"2007","journal-title":"J. Thorac. Oncol."},{"issue":"August (Suppl. 1)","key":"10.1016\/j.lungcan.2016.10.015_bib0065","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1038\/onc.2009.198","article-title":"Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors","volume":"28","author":"Gazdar","year":"2009","journal-title":"Oncogene"},{"issue":"January (2)","key":"10.1016\/j.lungcan.2016.10.015_bib0070","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1200\/JCO.2009.24.7049","article-title":"Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer","volume":"28","author":"Jackman","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2016.10.015_bib0075","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1371\/journal.pmed.0020073","article-title":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain","volume":"2","author":"Pao","year":"2005","journal-title":"PLoS Med."},{"issue":"June (6531)","key":"10.1016\/j.lungcan.2016.10.015_bib0080","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/375503a0","article-title":"Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16","volume":"375","author":"Lukas","year":"1995","journal-title":"Nature"},{"issue":"September (20)","key":"10.1016\/j.lungcan.2016.10.015_bib0085","doi-asserted-by":"crossref","first-page":"11891","DOI":"10.1073\/pnas.95.20.11891","article-title":"Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis","volume":"95","author":"Belinsky","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"November (5)","key":"10.1016\/j.lungcan.2016.10.015_bib0090","first-page":"1201","article-title":"Promoter hypermethylation of the p16 and Wif-1 genes as an independent prognostic marker in stage IA non-small cell lung cancers","volume":"35","author":"Yoshino","year":"2009","journal-title":"Int. J. Oncol."},{"issue":"November (11)","key":"10.1016\/j.lungcan.2016.10.015_bib0095","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1097\/JTO.0b013e3182a46c0c","article-title":"CDKN2A\/p16 inactivation mechanisms and their relationship to smoke exposure and molecular features in non-small-cell lung cancer","volume":"8","author":"Tam","year":"2013","journal-title":"J. Thorac. Oncol."},{"issue":"April (8)","key":"10.1016\/j.lungcan.2016.10.015_bib0100","first-page":"3419","article-title":"p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer","volume":"61","author":"Kim","year":"2001","journal-title":"Cancer Res."},{"issue":"June (14)","key":"10.1016\/j.lungcan.2016.10.015_bib0105","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1158\/1078-0432.CCR-07-4552","article-title":"Association of p16 homozygous deletions with clinicopathologic characteristics and EGFR\/KRAS\/p53 mutations in lung adenocarcinoma","volume":"14","author":"Iwakawa","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"March (6)","key":"10.1016\/j.lungcan.2016.10.015_bib0110","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1002\/ijc.21522","article-title":"Homozygous deletion of p16INK4a and tobacco carcinogen exposure in nonsmall cell lung cancer","volume":"118","author":"Kraunz","year":"2006","journal-title":"Int. J. Cancer"},{"issue":"July (3)","key":"10.1016\/j.lungcan.2016.10.015_bib0115","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/(SICI)1098-2264(199807)22:3<232::AID-GCC9>3.0.CO;2-X","article-title":"Association of CDKN2A(p16)\/CDKN2B(p15) alterations and homozygous chromosome arm 9p deletions in human lung carcinoma","volume":"22","author":"Hamada","year":"1998","journal-title":"Genes. Chromosomes Cancer"},{"key":"10.1016\/j.lungcan.2016.10.015_bib0120","series-title":"TNM Classification of Malignant Tumors","author":"Sobin","year":"2009"},{"issue":"January (2)","key":"10.1016\/j.lungcan.2016.10.015_bib0125","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"issue":"January (1)","key":"10.1016\/j.lungcan.2016.10.015_bib0130","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1309\/AJCPT94JVWIHBKRD","article-title":"Diagnostic usefulness of p16\/CDKN2A FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis","volume":"139","author":"Wu","year":"2013","journal-title":"Am. J. Clin. Pathol."},{"issue":"July (7)","key":"10.1016\/j.lungcan.2016.10.015_bib0135","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1136\/jcp.2010.076794","article-title":"FISH assay development for the detection of p16\/CDKN2A deletion in malignant pleural mesothelioma","volume":"63","author":"Chung","year":"2010","journal-title":"J. Clin. Pathol."},{"issue":"November (1)","key":"10.1016\/j.lungcan.2016.10.015_bib0140","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1200\/JCO.2010.31.8162","article-title":"Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer","volume":"29","author":"Brugger","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"April","key":"10.1016\/j.lungcan.2016.10.015_bib0145","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2147\/OTT.S60122","article-title":"Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients","volume":"7","author":"Li","year":"2014","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.lungcan.2016.10.015_bib0150","doi-asserted-by":"crossref","first-page":"20932","DOI":"10.1073\/pnas.0710370104","article-title":"MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib","volume":"104","author":"Bean","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lungcan.2016.10.015_bib0155","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","volume":"316","author":"Engelman","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.lungcan.2016.10.015_bib0160","doi-asserted-by":"crossref","first-page":"9479","DOI":"10.1158\/0008-5472.CAN-08-1643","article-title":"Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations","volume":"68","author":"Yano","year":"2008","journal-title":"Cancer Res."},{"issue":"August (15)","key":"10.1016\/j.lungcan.2016.10.015_bib0165","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1002\/cncr.28725","article-title":"The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer","volume":"120","author":"Zhao","year":"2014","journal-title":"Cancer"},{"issue":"May (19)","key":"10.1016\/j.lungcan.2016.10.015_bib0170","doi-asserted-by":"crossref","first-page":"13176","DOI":"10.1074\/jbc.274.19.13176","article-title":"Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1","volume":"274","author":"Gebhardt","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"December (24)","key":"10.1016\/j.lungcan.2016.10.015_bib0175","doi-asserted-by":"crossref","first-page":"9139","DOI":"10.1158\/0008-5472.CAN-04-1036","article-title":"An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors","volume":"64","author":"Amador","year":"2004","journal-title":"Cancer Res."},{"issue":"October (10)","key":"10.1016\/j.lungcan.2016.10.015_bib0180","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1097\/JTO.0b013e3181861d67","article-title":"Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancer","volume":"3","author":"Tiseo","year":"2008","journal-title":"J. Thorac. Oncol."},{"issue":"September (3)","key":"10.1016\/j.lungcan.2016.10.015_bib0185","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.lungcan.2014.06.016","article-title":"Sorensen BS: EGFR CA repeat polymorphism predict clinical outcome in EGFR mutation positive NSCLC patients treated with erlotinib","volume":"85","author":"Winther Larsen","year":"2014","journal-title":"Lung Cancer."},{"issue":"July (7)","key":"10.1016\/j.lungcan.2016.10.015_bib0190","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1172\/JCI73048","article-title":"CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance","volume":"124","author":"Park","year":"2014","journal-title":"J. Clin. Invest."},{"issue":"June (11)","key":"10.1016\/j.lungcan.2016.10.015_bib0195","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1158\/1078-0432.CCR-04-2661","article-title":"Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review","volume":"11","author":"Singhal","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"January (20)","key":"10.1016\/j.lungcan.2016.10.015_bib0200","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1200\/JCO.20.1.254","article-title":"Cooperative role of telomerase activity and p16 expression in the prognosis of non-small-cell lung cancer","volume":"20","author":"Gonz\u00e1lez-Quevedo","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"Febuary (1)","key":"10.1016\/j.lungcan.2016.10.015_bib0205","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/(SICI)1097-0215(19990219)84:1<49::AID-IJC10>3.0.CO;2-Y","article-title":"p16 inactivation in small-sized lung adenocarcinoma: its association with poor prognosis","volume":"84","author":"Kawabuchi","year":"1999","journal-title":"Int. J. Cancer"},{"issue":"July (7)","key":"10.1016\/j.lungcan.2016.10.015_bib0210","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.26","article-title":"Treating cancer with selective CDK4\/6 inhibitors","volume":"13","author":"O'Leary","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"July (7)","key":"10.1016\/j.lungcan.2016.10.015_bib0215","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1093\/neuonc\/nos114","article-title":"p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells","volume":"14","author":"Cen","year":"2012","journal-title":"Neuro Oncol."},{"issue":"October (10)","key":"10.1016\/j.lungcan.2016.10.015_bib0220","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1097\/JTO.0b013e3182295745","article-title":"A comprehensive analysis of p16 expression, gene status, and promoter hypermethylation in surgically resected non-small cell lung carcinomas","volume":"6","author":"Sterlacci","year":"2011","journal-title":"J. Thorac. Oncol."},{"issue":"September (5)","key":"10.1016\/j.lungcan.2016.10.015_bib0225","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/PAP.0b013e3181832320","article-title":"Bladder cancer detection using FISH (UroVysion assay)","volume":"15","author":"Halling","year":"2008","journal-title":"Adv. Anat. Pathol."},{"issue":"October (10)","key":"10.1016\/j.lungcan.2016.10.015_bib0230","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/iju.12509","article-title":"Recurrence and progression in patients with non-muscle invasive bladder cancer: prognostic models including multicolor fluorescence in situ hybridization molecular grading","volume":"21","author":"Lodde","year":"2014","journal-title":"Int. J. Urol."},{"issue":"January (3)","key":"10.1016\/j.lungcan.2016.10.015_bib0235","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1200\/JCO.2005.02.081","article-title":"Ewing sarcomas with p53 mutation or p16\/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse","volume":"23","author":"Huang","year":"2005","journal-title":"J. Clin. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500216305141?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500216305141?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T04:36:19Z","timestamp":1589690179000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500216305141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":47,"alternative-id":["S0169500216305141"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2016.10.015","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Coexistence of p16\/CDKN2A homozygous deletions and activating EGFR mutations in lung adenocarcinoma patients signifies a poor response to EGFR-TKIs","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2016.10.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}